Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E. Lyke, William Edward Witt, Andrezza Campos Chagas et al.|The Lancet Infectious Diseases|2023Cited by 42